Glenn Markov, Rejuvenation Technologies co-founder & COO (L) and John Ramunas, co-founder & CEO (Photographer: Erin Beach)

Ex­clu­sive: Khosla Ven­tures leads seed round in mR­NA biotech look­ing to re­verse ag­ing by length­en­ing telom­eres

A tiny biotech start­up called Re­ju­ve­na­tion Tech­nolo­gies is the lat­est to chase a mas­sive am­bi­tion in re­vers­ing ag­ing, a buzzy and of­ten con­tro­ver­sial re­search area emerg­ing in biotech.

Re­ju­ve­na­tion an­nounced Wednes­day it has raised $10.6 mil­lion in a seed round led by Khosla Ven­tures. The Cal­i­for­nia start­up, found­ed by two Stan­ford PhD sci­en­tists, be­lieves now is the right time to de­vel­op drugs that length­en telom­eres, which act like pro­tec­tive caps on the ends of chro­mo­somes. The field has ex­pe­ri­enced plen­ty of ups and downs over the last cou­ple of decades. No biotech has yet to suc­cess­ful­ly de­vel­op a drug tar­get­ing these DNA se­quences.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.